Anika Therapeutics, Inc. (ANIK)
21.42
+0.33
(+1.56%)
USD |
NASDAQ |
Oct 23, 16:00
21.42
0.00 (0.00%)
Pre-Market: 20:00
Anika Therapeutics Enterprise Value : 273.50M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 273.50M |
| October 22, 2026 | 269.09M |
| October 21, 2026 | 262.53M |
| October 20, 2026 | 260.39M |
| October 19, 2026 | 257.44M |
| October 16, 2026 | 254.23M |
| October 15, 2026 | 263.73M |
| October 14, 2026 | 257.84M |
| October 13, 2026 | 261.59M |
| October 12, 2026 | 260.79M |
| October 09, 2026 | 248.88M |
| October 08, 2026 | 244.19M |
| October 07, 2026 | 248.21M |
| October 06, 2026 | 242.72M |
| October 05, 2026 | 250.88M |
| October 02, 2026 | 242.45M |
| October 01, 2026 | 245.93M |
| September 30, 2026 | 249.95M |
| September 29, 2026 | 253.76M |
| September 28, 2026 | 263.60M |
| September 25, 2026 | 259.45M |
| September 24, 2026 | 257.58M |
| September 23, 2026 | 259.52M |
| September 22, 2026 | 266.41M |
| September 21, 2026 | 263.87M |
| Date | Value |
|---|---|
| September 18, 2026 | 265.34M |
| September 17, 2026 | 268.28M |
| September 16, 2026 | 265.74M |
| September 15, 2026 | 266.68M |
| September 14, 2026 | 270.42M |
| September 11, 2026 | 266.01M |
| September 10, 2026 | 267.75M |
| September 09, 2026 | 266.28M |
| September 08, 2026 | 268.42M |
| September 04, 2026 | 265.34M |
| September 03, 2026 | 267.88M |
| September 02, 2026 | 275.24M |
| September 01, 2026 | 269.35M |
| August 31, 2026 | 266.14M |
| August 28, 2026 | 269.22M |
| August 27, 2026 | 265.74M |
| August 26, 2026 | 276.98M |
| August 25, 2026 | 273.23M |
| August 24, 2026 | 272.43M |
| August 21, 2026 | 278.32M |
| August 20, 2026 | 272.43M |
| August 19, 2026 | 271.36M |
| August 18, 2026 | 275.51M |
| August 17, 2026 | 274.17M |
| August 14, 2026 | 274.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Perspective Therapeutics, Inc. | -49.23M |
| MiMedx Group, Inc. | 451.15M |
| ABVC BioPharma, Inc. | 31.57M |
| Intuitive Surgical, Inc. | 152.82B |
| Precigen, Inc. | 2.276B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.309M |
| Revenue (Quarterly) | 32.61M |
| Total Expenses (Quarterly) | 29.30M |
| EPS Diluted (Quarterly) | 0.2412 |
| Gross Profit Margin (Quarterly) | 65.15% |
| Profit Margin (Quarterly) | 10.15% |
| Earnings Yield | -1.28% |
| Normalized Earnings Yield | -1.279 |